Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Clara Ibarguren-QuilesMultidisciplinary and Translational Microbiology group (MicroTM), Biomedical Research Institute of A Coruña (INIBIC), Microbiology Service, University Hospital of A Coruña (CHUAC), University of A Coruña (UDC), A Coruña, Spain.ORCID 0009-0004-3909-7257
Lucía BlascoMultidisciplinary and Translational Microbiology group (MicroTM), Biomedical Research Institute of A Coruña (INIBIC), Microbiology Service, University Hospital of A Coruña (CHUAC), University of A Coruña (UDC), A Coruña, Spain.ORCID 0000-0002-4039-4142
Carla López-CausapeStudy Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA) on behalf of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), Madrid, Spain.ORCID 0000-0003-2228-2005
Inés BleriotMultidisciplinary and Translational Microbiology group (MicroTM), Biomedical Research Institute of A Coruña (INIBIC), Microbiology Service, University Hospital of A Coruña (CHUAC), University of A Coruña (UDC), A Coruña, Spain.ORCID 0000-0002-1846-4693
Laura Fernández-GarcíaMultidisciplinary and Translational Microbiology group (MicroTM), Biomedical Research Institute of A Coruña (INIBIC), Microbiology Service, University Hospital of A Coruña (CHUAC), University of A Coruña (UDC), A Coruña, Spain.ORCID 0000-0003-3069-9759
Lucia ArmanMultidisciplinary and Translational Microbiology group (MicroTM), Biomedical Research Institute of A Coruña (INIBIC), Microbiology Service, University Hospital of A Coruña (CHUAC), University of A Coruña (UDC), A Coruña, Spain.ORCID 0009-0008-6209-327X
Antonio Barrio-PujanteMultidisciplinary and Translational Microbiology group (MicroTM), Biomedical Research Institute of A Coruña (INIBIC), Microbiology Service, University Hospital of A Coruña (CHUAC), University of A Coruña (UDC), A Coruña, Spain.ORCID 0009-0006-8173-0823
Concha Ortiz-CartagenaMultidisciplinary and Translational Microbiology group (MicroTM), Biomedical Research Institute of A Coruña (INIBIC), Microbiology Service, University Hospital of A Coruña (CHUAC), University of A Coruña (UDC), A Coruña, Spain.ORCID 0000-0001-6632-1454
Belén AracilReference Laboratory of Antimicrobial Resistance, National Center of Microbiology, Health Institute Carlos III, Majadahonda, Madrid, Spain.
Olaya Menéndez-RodriguezStudy Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA) on behalf of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), Madrid, Spain.ORCID 0009-0002-5241-2819
Luis Mariñas-PardoDepartamento de Desarrollo de Medicamentos de Terapias Avanzadas (DDMTA), Instituto de Investigación de Enfermedades Raras (IIER), Carlos III Health Institute, Majadahonda, Madrid, Spain.
Rafael CantónStudy Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA) on behalf of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), Madrid, Spain.ORCID 0000-0003-1675-3173
Antonio Oliver *Study Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA) on behalf of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), Madrid, Spain.ORCID 0000-0001-9327-1894
María Tomás *Multidisciplinary and Translational Microbiology group (MicroTM), Biomedical Research Institute of A Coruña (INIBIC), Microbiology Service, University Hospital of A Coruña (CHUAC), University of A Coruña (UDC), A Coruña, Spain.ORCID 0000-0003-4501-0387
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The current health crisis caused by multidrug-resistant (MDR) pathogens is one of the health problems of most concern globally. Infections caused by these pathogens, such as
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Identification and functional insights into new phage tail-like bacteriocins targeting · full record | OpenQuestion